Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more
Seoulin Bioscience Co.Ltd (038070) - Total Assets
Latest total assets as of September 2025: ₩113.52 Billion KRW
Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) holds total assets worth ₩113.52 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Seoulin Bioscience Co.Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Seoulin Bioscience Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Seoulin Bioscience Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Seoulin Bioscience Co.Ltd's total assets of ₩113.52 Billion consist of 58.9% current assets and 41.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩8.95 Billion | 0.0% |
| Accounts Receivable | ₩9.28 Billion | 9.1% |
| Inventory | ₩26.25 Billion | 25.9% |
| Property, Plant & Equipment | ₩16.63 Billion | 16.4% |
| Intangible Assets | ₩502.88 Million | 0.5% |
| Goodwill | ₩373.89 Million | 0.4% |
Asset Composition Trend (2013–2024)
This chart illustrates how Seoulin Bioscience Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seoulin Bioscience Co.Ltd's current assets represent 58.9% of total assets in 2024, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 6.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 25.9% of total assets.
Seoulin Bioscience Co.Ltd Competitors by Total Assets
Key competitors of Seoulin Bioscience Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Seoulin Bioscience Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Seoulin Bioscience Co.Ltd generates 0.74x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Seoulin Bioscience Co.Ltd generates $ 2.87 in net profit.
Seoulin Bioscience Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.57 | 4.98 | 3.06 |
| Quick Ratio | 1.67 | 3.02 | 2.20 |
| Cash Ratio | 0.00 | 0.71 | 0.00 |
| Working Capital | ₩39.91 Billion | ₩ 45.68 Billion | ₩ 27.93 Billion |
Seoulin Bioscience Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Seoulin Bioscience Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -11.0% |
| Total Assets | ₩101.52 Billion |
| Market Capitalization | $27.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seoulin Bioscience Co.Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Seoulin Bioscience Co.Ltd's assets decreased by 11.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Seoulin Bioscience Co.Ltd (2013–2024)
The table below shows the annual total assets of Seoulin Bioscience Co.Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩101.52 Billion | -11.02% |
| 2023-12-31 | ₩114.10 Billion | -15.40% |
| 2022-12-31 | ₩134.87 Billion | -1.24% |
| 2021-12-31 | ₩136.57 Billion | +74.53% |
| 2020-12-31 | ₩78.25 Billion | -3.05% |
| 2019-12-31 | ₩80.71 Billion | +13.49% |
| 2018-12-31 | ₩71.11 Billion | +0.10% |
| 2017-12-31 | ₩71.04 Billion | +6.87% |
| 2016-12-31 | ₩66.47 Billion | +0.55% |
| 2015-12-31 | ₩66.10 Billion | +8.87% |
| 2014-12-31 | ₩60.72 Billion | +0.55% |
| 2013-12-31 | ₩60.39 Billion | -- |